# Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection

> **NCT04526912** · PHASE1 · TERMINATED · sponsor: **Viela Bio** · enrollment: 10 (actual)

## Conditions studied

- Acute Lung Injury

## Interventions

- **DRUG:** VIB7734
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04526912
- **Lead sponsor:** Viela Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-28
- **Primary completion:** 2021-04-08
- **Final completion:** 2021-05-19
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Study met predefined futility criteria for efficacy endpoints.
- **Last updated:** 2021-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04526912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04526912, "Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04526912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*